title: Overall interleukin-6 production exceeds 7 mg/day in multiple myeloma complicated by sepsis.
abstract: We previously reported that injection of anti-IL-6 monoclonal antibody (mAb) in a patient with multiple myeloma (MM) induced the circulation of high amounts of IL-6 in the form of IL-6/anti-IL-6 monomeric complexes. This made it possible to estimate overall daily IL-6 production in patients in vivo, which had not been achieved in animals or humans before. In this study, estimations are given for a patient with MM who developed Escherichia coli sepsis during anti-IL-6 mAb. During the first 12 days, the overall IL-6 production was estimated at 1.5 to 2.0 micrograms/day. On day 13, serum IL-6 concentration, in the form of IL-6/anti-IL-6 complexes, increased 1000-fold and was 1.7 x 10(6) pg/ml, in relation with the development of E. coli sepsis. Overall IL-6 production was estimated to be greater than 7 mg/day, i.e. 3500 times higher than before sepsis. Serum IL-6 levels in the form of monomeric immune complexes remained very high for 20 days after sepsis indicating the persistence of very high overall IL-6 production (100 to 3500-fold greater than pre-sepsis production). This study demonstrates a considerable and persistent potential for IL-6 production in this patient during and after sepsis.
authors.affiliation: Laboratoire d'Oncogénèse Immunohohematologique, Institut de Biologie, Nantes, France.
authors.forename: Z Y
authors.initials: ZY
authors.lastname: Lu
authors.forename: H
authors.initials: H
authors.lastname: Brailly
authors.forename: J F
authors.initials: JF
authors.lastname: Rossi
authors.forename: J
authors.initials: J
authors.lastname: Wijdenes
authors.forename: R
authors.initials: R
authors.lastname: Bataille
authors.forename: B
authors.initials: B
authors.lastname: Klein
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000936:Antigen-Antibody Complex / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D004927:Escherichia coli Infections / Q000097:blood / Q000150:complications* / Q000276:immunology*; D006801:Humans; D015850:Interleukin-6 / Q000096:biosynthesis* / Q000097:blood; D007700:Kinetics; D009101:Multiple Myeloma / Q000097:blood / Q000150:complications* / Q000276:immunology*; D000093242:Interleukin-6 Inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D000936:Antigen-Antibody Complex; D002097:C-Reactive Protein; D015850:Interleukin-6; D000093242:Interleukin-6 Inhibitors